An interventional study of Theta burst stimulation active coil and Sham coil in Parkinsons Disease (PD) and Anxiety, sponsored by HealthPartners Institute. Enrolling by invitation at 1 site in United States. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by HealthPartners Institute · Not applicable, Interventional, and Treatment
Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 963rd largest by planned enrollment of the 1,256 interventional ones that give a count, is one of 78 that started in 2025, is one of 585 with no phase, reaches primary completion later than 235 of the 384 other live ones, and was the 1,524th registered.
4,576 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, United Kingdom
Ages 40–85
Medical University of South Carolina · Sites in United States
Ages 50–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 749 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,649 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 78 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,256 interventional studies, 78 across the 379 observational. Of the 1,139 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,649 have an industry lead sponsor. The 10 most frequent:
HealthPartners Institute is the lead sponsor of 167 studies on the registry; 20 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
HealthPartners Institute has 4 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
137 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT05558189Stanford UniversityVibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients | 2026-11-21 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
Add all 137 to your calendar (.ics) → With an account.
Among the 1,649 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's dementia. Anxiety in PD is common, has major effects on quality of life and contributes to increased disability. The reported prevalence of anxiety in PD ranges widely and is estimated up to 40%. Treatment with oral medications is not always effective or tolerated. TMS has been shown to be effective and safe in anxiety and general anxiety disorder (GAD), but there is only limited data available for Transcranial Magnetic Stimulation (TMS) treatment of anxiety in PD. Area 8Av is a parcellation based on Human connectome project within the left prefrontal cortex and is associated with GAD. Given the area's associations with mood disorders, its functional connectivity with large-scale brain networks involved in PD, and its anatomical accessibility by TMS, this may be an important target for anxiety in PD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive treatment with intermittent theta burst stimulation (iTBS) with the active coil. There will be a total of 27 sessions over a 3-week period with 3 sessions per day. All subjects will receive iTBS to the left 8Av region. Total participation will be 8-12 weeks.
Device: Theta burst stimulation active coil
Subjects will receive treatment with sham coil. There will be a total of 27 treatments over a 3-week period. Coil will be placed over the same region as the experimental group. Total participation will be 8-12 weeks.
Device: Sham coil
MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 90%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz; Session length: 10 min; Time between sessions: 50 minutes.
Also known as: Transmagnetic stimulation, MagVenture
MagVenture TMS Therapy sham coil
Recruitment Rate
Percentage of participant who enroll and consent based on those contacted. A higher percentage indicates higher feasibility.
Time frame: screening
Participation Rate
Percentage of participant who start treatment after enrollment. A higher percentage indicates higher feasibility.
Time frame: 3 weeks
Fidelity
Percentage of participant who complete all treatment sessions. A higher percentage indicates higher fidelity.
Time frame: 2 weeks
Completion Rate
Percentage of participant who complete 7 of the 9 treatment visits. A higher percentage indicates higher completion.
Time frame: 2 weeks
Adverse Events Rate - Safety
Percentage of participant with adverse events. A lower percentage indicates a safer treatment.
Time frame: up to 12 weeks
Adverse Events Safety
Frequency of each adverse event. A higher frequency indicates a less safe treatment.
Time frame: up to 12 weeks
Average change between baseline and 1 week post-treatment TMS vs Sham - Anxiety Scale
The Parkinson Anxiety Scale (PAS) is a 12-item scale developed to assess anxiety in individuals with Parkinson's disease (PD). Items are scored on a 5 point Likert scale. Range \[0-48\]. A higher score indicates higher anxiety
Time frame: baseline, 1 week post-treatment
Average change between baseline and 1 week post-treatment TMS vs Sham - Cognitive scale
The Montreal Cognitive Assessment (MoCA) is a brief cognitive screening measure that has been validated for use among individuals with Alzheimer's disease. The total score for this test is 30 points, but one point will be added for individuals with ≤ 12 years of education. The cutoff point for normal cognition is 26/30 in the general population and in individuals with Parkinson's Disease. This will be conducted by clinical staff and gathered as part of the chart review. Range: \[0-30\]. Higher score indicates higher cognitive health.
Time frame: baseline, 1 week post-treatment
Average change between baseline and 1 week post-treatment TMS vs Sham - Mood
The Geriatric depression scale (GDS-15) short form is a screening measure for depression in older patients. Range \[0-15\]. A higher score indicates more depressive symptoms.
Time frame: baseline, 1 week post-treatment
Average change between baseline and 1 week post-treatment TMS vs Sham - Motor
The United Parkinson's Disease Rating Scale (UPDRS) is the most widely used clinical rating scale for Parkinson's disease. Only part III of the rating scale is used, which is a clinician-scored monitored motor evaluation, allowing ratings from 0 (no symptoms) to 4 (severe symptoms) for each Parkinson's motor symptom. The Movement Disorders Society (MDS) commissioned a revision of the scale, resulting in a new version, termed the MDS sponsored UPDRS revision (MDS-UPDRS). In this study, the MDS-UDPRS version will be used. Range \[7-86\]. A higher score indicates more severe motor symptoms.
Time frame: baseline, 1 week post-treatment
Pre-post change between baseline and 1 week post-treatment within individuals in active TMS group - Anxiety Scale
The Parkinson Anxiety Scale (PAS) is a 12-item scale developed to assess anxiety in individuals with Parkinson's disease (PD). Items are scored on a 5 point Likert scale. Range \[0-48\]. A higher score indicates higher anxiety
Time frame: baseline, 1 week post-treatment
Pre-post change between baseline and 1 week post-treatment within individuals in active TMS group - Cognitive scale
The Montreal Cognitive Assessment (MoCA) is a brief cognitive screening measure that has been validated for use among individuals with Alzheimer's disease. The total score for this test is 30 points, but one point will be added for individuals with ≤ 12 years of education. The cutoff point for normal cognition is 26/30 in the general population and in individuals with Parkinson's Disease. This will be conducted by clinical staff and gathered as part of the chart review. Range: \[0-30\]. Higher score indicates higher cognitive health.
Time frame: baseline, 1 week post-treatment
Pre-post change between baseline and 1 week post-treatment within individuals in active TMS group - Mood
The Geriatric depression scale (GDS-15) short form is a screening measure for depression in older patients. Range \[0-15\]. A higher score indicates more depressive symptoms.
Time frame: baseline, 1 week post-treatment
Pre-post change between baseline and 1 week post-treatment within individuals in active TMS group - Motor
The United Parkinson's Disease Rating Scale (UPDRS) is the most widely used clinical rating scale for Parkinson's disease. Only part III of the rating scale is used, which is a clinician-scored monitored motor evaluation, allowing ratings from 0 (no symptoms) to 4 (severe symptoms) for each Parkinson's motor symptom. The Movement Disorders Society (MDS) commissioned a revision of the scale, resulting in a new version, termed the MDS sponsored UPDRS revision (MDS-UPDRS). In this study, the MDS-UDPRS version will be used. Range \[7-86\]. A higher score indicates more severe motor symptoms.
Time frame: baseline, 1 week post-treatment
Responder Rate
Percentage of participants that respond to treatment based on improvement in symptom specific scales. Higher percentage indicates more successful treatment
Time frame: baseline, 1 week post treatment
Explore the effect of TMS treatment on functional connectivity with Left 8 Av. - Change
Average change between baseline and 1-week post-treatment will be compared between groups (TMS vs Sham) in anomaly burden.
Time frame: baseline, 1-week post treatment
Explore the effect of TMS treatment on functional connectivity with Left 8 Av. - Names and number of anomalous parcellations
Names and number of anomalous parcellations identified using connectivity analysis at baseline and 1-week post treatment will be described for each participant and tabulated for each arm.
Time frame: baseline, 1-week post treatment
Plan to share: No — No identifiable data will be shared with other researchers.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.
Of 1,293 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 29 months is above that.
Counting every sponsor, half of 1,369 studies reached it within 25 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.